Clinical Trials Browser

Phase 2/3 × Androgen Antagonists × 90 days × Clear all

NCT07426055 2026-02-23

PRO-BOOST-LC

Phase 2/3 Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07426094 2026-02-23

PRO-BOOST-N

Phase 2/3 Not yet recruiting

Neoplasm Metastasis, Prostatic Neoplasms